Projects per year
Personal profile
Biography
Professor Andrew Perkins
Perkins Group - Blood Cancer Genomics
Andrew is a Professor in the Australian Centre for Blood Diseases, within the School of Translational Medicine. Dr Perkins trained at RPA Hospital in Sydney in clinical and laboratory haematology, undertook his PhD in genetics at Walter and Eliza Hall Institute, then post-doctoral studies at Harvard University before returning to Australia in 1997.
Professor Perkins is a clinician-scientist who seeks to understand transcriptional control networks which underpin normal blood stem cell production and blood cancers. We intend to harness this knowledge to cure inherited or acquired human blood diseases.
Supervision interests
Extensive experience in RHD supervision:
26 PhD students
25 BSc Hons students
5 Masters students
1 BSc (Med) student
4 Masters of Genome Analytics Internships
Clinical activities
Head of Genomic Medicine, Alfred Health, Melbourne
Professor of Haematology, The Alfred Hospital, Melbourne
Clinical Lead in Myeloproliferative Neoplasms
Monash teaching commitment
Teaching in HUP3022 - Haematological Malignancies
Teaching in HUP3990 - Third Year Research Projects
GNA5041: Masters of Genome Analytics, second year lecture series
GNA5930: Masters in Genome Analytics Internships in Genome Curation
Community service
Australia Leukaemia and Lymphoma Group Subcommittee for Myeloproliferative Neoplasms - 2014 - ongoing
Lorne Genome Organising Committee 2016-2024
NHMRC GRPs in Oncology and Biochemistry 2007-2018
NHMRC Investigator Grant Review Panel 2020-2021
Ideas GRP 2021
Genomic Health Futures Mission GRP 2021-23
External positions
Head of Genomic Medicine Alfred Health, Alfred Hospital
1 Jul 2020 → …
Professor of Haematology, Alfred Hospital
3 Jul 2017 → …
University of Queensland
Research area keywords
- KLF1
- Erythropoiesis
- Myelodysplasia
- Leukaemia
- Transcription factors
- Genome Editing
- Genomics
- Cancer Cell Biology
Expertise related to UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):
-
SDG 3 Good Health and Well-being -
SDG 7 Affordable and Clean Energy
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
A Phase 1, Open-Label, Multicenter Study of INCA035784 in Participants With Myeloproliferative Neoplasms
Perkins, A. (Primary Chief Investigator (PCI))
16/10/25 → 15/10/29
Project: Research
-
ASCENDANCE - ASCiminib Evaluation in Newly diagnosed CML with Dasatinib to Augment response in Complex genomic Etiology
Perkins, A. (Primary Chief Investigator (PCI))
13/08/25 → 12/08/27
Project: Research
-
A Phase 3, Randomized, Double-blind, Add-on Study Evaluating the Safety and Efficacy of Navtemadlin Plus Ruxolitinib vs Placebo Plus Ruxolitinib in JAK Inhibitor-Naïve Patients with Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
Perkins, A. (Primary Chief Investigator (PCI))
6/11/24 → 5/11/26
Project: Research
-
Defining the circulating genome of high-risk plasma cell disorders to improve risk stratification and clinical management
Mithraprabhu, S. (Primary Chief Investigator (PCI)), Khong, T. (Chief Investigator (CI)), Reynolds, J. (Chief Investigator (CI)), Murray, D. (Chief Investigator (CI)), Shah, J. (Chief Investigator (CI)), Wellard, C. (Chief Investigator (CI)), Spencer, A. (Associate Investigator (AI)), Ross, J. (Associate Investigator (AI)), Perkins, A. (Associate Investigator (AI)), Marks, A. (Associate Investigator (AI)), Beer, H. (Associate Investigator (AI)) & Henderson, M. (Associate Investigator (AI))
1/04/24 → 31/12/26
Project: Research
-
A Phase 1, Open-Label, Multicenter Study of INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms
Perkins, A. (Primary Chief Investigator (PCI))
12/09/23 → 12/09/26
Project: Research
-
Targeting enhancer RNAs to silence transcription
Perkins, A. C., 26 Mar 2026, In: Blood. 147, 13, p. 1389-1391 3 p.Research output: Contribution to journal › Editorial › Other › peer-review
Open Access -
Clinical utility of panel-based genetic sequencing for von Willebrand disease
Ramanan, R., Van Laer, C., Baert, S., Kint, C., Van Geet, C., Van Thillo, Q., Verhamme, P., Vanassche, T., McFadyen, J. D., Perkins, A. C., Tran, H. A., Labarque, V. & Freson, K., Feb 2025, In: Research and Practice in Thrombosis and Haemostasis. 9, 2, 13 p., 102730.Research output: Contribution to journal › Article › Research › peer-review
Open Access5 Link opens in a new tab Citations (Scopus) -
Longitudinal Assessment of Transfusion Intensity in Patients With JAK Inhibitor–Naive or –Experienced Myelofibrosis Treated With Momelotinib
Harrison, C. N., Mesa, R., Talpaz, M., Gupta, V., Gerds, A. T., Perkins, A., Goh, Y. T., Fox, M. L., McLornan, D., Palmer, J., Foltz, L., Vannucchi, A., Koschmieder, S., Passamonti, F., Lee, S. E., Ellis, C., Strouse, B., Gonzalez Carreras, F. J. & Oh, S. T., Mar 2025, In: Clinical Lymphoma, Myeloma and Leukemia. 25, 3, p. 199-211 13 p.Research output: Contribution to journal › Article › Research › peer-review
Open Access4 Link opens in a new tab Citations (Scopus) -
Reduced PI3K(p110α) induces atrial myopathy, and PI3K-related lipids are dysregulated in athletes with atrial fibrillation
Bass-Stringer, S., Bernardo, B. C., Yildiz, G. S., Matsumoto, A., Kiriazis, H., Harmawan, C. A., Tai, C. M. K., Chooi, R., Bottrell, L., Ezeani, M., Donner, D. G., D'Elia, A. A., Ooi, J. Y. Y., Mellett, N. A., Luo, J., Masterman, E. I., Janssens, K., Olshansky, G., Howden, E. J. & Cross, J. H. & 13 others, , Dec 2025, In: Journal of Sport and Health Science. 14, 18 p., 101023.Research output: Contribution to journal › Article › Research › peer-review
Open Access6 Link opens in a new tab Citations (Scopus) -
Mutations in linker-2 of KLF1 impair expression of membrane transporters and cytoskeletal proteins causing hemolysis
Huang, S., Reed, C., Ilsley, M., Magor, G., Tallack, M., Landsberg, M., Mitchell, H., Gillinder, K. & Perkins, A., Dec 2024, In: Nature Communications. 15, 1, 16 p., 7019.Research output: Contribution to journal › Article › Research › peer-review
Open Access3 Link opens in a new tab Citations (Scopus)
Prizes
-
Albert G. Baikie Memorial Medal
Perkins, A. (Recipient), 1991
Prize: Prize (including medals and awards)
-
-
-
Lucille P. Markey Postdoctoral Research Fellowship
Perkins, A. (Recipient), 1993
Prize: Competitive Fellowships
-
Activities
-
Lorne Genome Conference 2019
Perkins, A. (Organiser)
17 Feb 2019 → 19 Feb 2019Activity: Participating in or organising an event types › Contribution to conference
-
Icahn School of Medicine at Mount Sinai
Perkins, A. (Visiting researcher)
11 Dec 2019Activity: Visiting an external institution types › Visiting an external academic institution
-
Investigator Grant Panel Committee Member
Perkins, A. (Executive Member)
Mar 2019 → May 2019Activity: External Academic Engagement › Peer review panel or committee
-
Novartis Pharmaceuticals Australia Pty Limited (External organisation)
Perkins, A. (Member)
21 Feb 2019Activity: Industry, Government and Philanthropy Engagement and Partnerships › Consultancy
-
Australian Leukaemia and Lymphoma Group 2019
Perkins, A. (Invited speaker)
10 May 2019Activity: Participating in or organising an event types › Contribution to conference